Jessica Menis

3.4k total citations · 2 hit papers
76 papers, 1.9k citations indexed

About

Jessica Menis is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, Jessica Menis has authored 76 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 49 papers in Pulmonary and Respiratory Medicine, 49 papers in Oncology and 15 papers in Cancer Research. Recurrent topics in Jessica Menis's work include Lung Cancer Treatments and Mutations (41 papers), Lung Cancer Diagnosis and Treatment (23 papers) and Cancer Immunotherapy and Biomarkers (17 papers). Jessica Menis is often cited by papers focused on Lung Cancer Treatments and Mutations (41 papers), Lung Cancer Diagnosis and Treatment (23 papers) and Cancer Immunotherapy and Biomarkers (17 papers). Jessica Menis collaborates with scholars based in Italy, France and Belgium. Jessica Menis's co-authors include Lizza Hendriks, Antonio Passaro, Egbert F. Smit, Solange Peters, Benjamin Solomon, Ursula Nestle, Tony Mok, David Planchard, Keith M. Kerr and Giulia Veronesi and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and International Journal of Molecular Sciences.

In The Last Decade

Jessica Menis

74 papers receiving 1.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

2023 370 citations Lizza Hendriks, Jessica Menis et al. Annals of Oncology profile →
Non-oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

2023 286 citations Lizza Hendriks, Jessica Menis et al. Annals of Oncology profile →

Peers

Countries citing papers authored by Jessica Menis

Since Specialization

Citations

This map shows the geographic impact of Jessica Menis's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jessica Menis with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jessica Menis more than expected).

Fields of papers citing papers by Jessica Menis

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jessica Menis. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jessica Menis. The network helps show where Jessica Menis may publish in the future.

Co-authorship network of co-authors of Jessica Menis

This figure shows the co-authorship network connecting the top 25 collaborators of Jessica Menis. A scholar is included among the top collaborators of Jessica Menis based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jessica Menis. Jessica Menis is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	De-Escalation Strategies With Immune Checkpoint Blockers in Non–Small Cell Lung Cancer: Do We Already Have Enough Evidence? 2025 ·Journal of Clinical Oncology ·Jordi Remón, (unknown), Paolo Bironzo, Francesco Cortiula, Jessica Menis, Mariana Brandão, Jarushka Naidoo, Robin M.J.M. van Geel, Noemı́ Reguart, Óscar Arrieta, Giannis Mountzios, Lizza Hendriks, Benjamin Besse	6
2	Implementation outcomes of early nutritional screening and referral for patients with thoracic cancers 2024 ·Clinical Nutrition Open Science ·Lorenzo Belluomini, Alice Avancini, Ilaria Trestini, (unknown), Marco Sposito, Jessica Menis, Daniela Tregnago, Michèle Milella, Sara Pilotto	1
3	1006P Phase I dose escalation study of HFB200603, a best-in-class BTLA antagonist monoclonal antibody (mAb), in monotherapy and in combination with the anti-PD-1 mAb tislelizumab (TIS) in adult patients (pts) with advanced solid tumors 2024 ·Annals of Oncology ·M. De Miguel, (unknown), Víctor Moreno, (unknown), Jessica Menis, Giuseppe Daniele, Anthony B. El-Khoueiry, Alexander I. Spira, Alessia Gravina, Anthony J. Olszanski, (unknown), (unknown), (unknown), (unknown), (unknown), William D. Hedrich, (unknown), Jinping Gan, Xiaorong Shi, Robert H.I. Andtbacka	0
4	Progresses and Pitfalls of Epigenetics in Solid Tumors Clinical Trials 2024 ·International Journal of Molecular Sciences ·(unknown), (unknown), Anna Reni, (unknown), Silvia Palmerio, Jessica Menis, Andrea Zivi, Stefano Milleri, Michèle Milella	3
5	Perioperative Treatment Strategies in EGFR-Mutant Early-Stage NSCLC: Current Evidence and Future Challenges 2023 ·Journal of Thoracic Oncology ·Jordi Remón, Stephanie P.L. Saw, Francesco Cortiula, Pawan Kumar Singh, Jessica Menis, Giannis Mountzios, Lizza Hendriks	17
6	Selpercatinib in RET-fusion positive metastatic non-small cell lung cancer: achievements and gray areas 2022 ·Expert Review of Anticancer Therapy ·Lorenzo Belluomini, Alice Avancini, (unknown), (unknown), Marco Sposito, Jessica Menis, Daniela Tregnago, Ilaria Trestini, Miriam Grazia Ferrara, Emilio Bria, Michèle Milella, Sara Pilotto	4
7	Anticipating EGFR Targeting in Early Stages of Lung Cancer: Leave No Stone Unturned 2021 ·Cells ·Lorenzo Belluomini, (unknown), Michele Simbolo, Riccardo Nocini, Ilaria Trestini, Alice Avancini, Daniela Tregnago, Miriam Grazia Ferrara, (unknown), (unknown), Anna Caliò, Emilio Bria, Aldo Scarpa, Michèle Milella, Jessica Menis, Sara Pilotto	4
8	Real-World Data on Treatment Outcomes in EGFR -Mutant Non-Small-Cell Lung Cancer Patients Receiving Osimertinib in Second or Further Lines 2021 ·Future Oncology ·Alessandro Dal Maso, (unknown), Alessandra Ferro, Sara Pilotto, Fabiana Letizia Cecere, Alessandro Follador, Valentina Polo, Alessandro Del Conte, Giulia Sartori, (unknown), (unknown), Stefano Indraccolo, (unknown), Giovanna De Maglio, Jessica Menis, Laura Bonanno, Fiorella Calabrese, Valentina Guarneri, Pierfranco Conté, Giulia Pasello	8
9	Exploring the role of respiratory microbiome in lung cancer: A systematic review 2021 ·Critical Reviews in Oncology/Hematology ·Fabiana Perrone, Lorenzo Belluomini, Marco Mazzotta, Maristella Bianconi, Vincenzo Di Noia, F. Meacci, Michele Montrone, Daniele Pignataro, Arsela Prelaj, Silvia Rinaldi, Marco Russano, Giulia Sartori, Paolo Bironzo, Francesco Facchinetti, Jessica Menis, Marcello Tiseo, Domenico Galetta, Silvia Novello, Sara Pilotto	24
10	1640P Impact of COVID-19 vaccination campaign on psychological status in cancer patients (pts) 2021 ·Annals of Oncology ·Daniela Tregnago, Sara Pilotto, Lorenzo Belluomini, Jessica Menis, Elena Fiorio, Michele Pavarana, Massimiliano Casali, L. Benini, (unknown), (unknown), (unknown), Ilaria Trestini, Alice Avancini, (unknown), (unknown), Michela Rimondini, Lidia Del Piccolo, (unknown), Michèle Milella	1
11	How covid-19 pandemic impacted integrated care pathways for lung cancer: the experience of two Italian centers in veneto region 2020 ·Tumori ·Giulia Pasello, Jessica Menis, Sara Pilotto, (unknown), Federica Pezzuto, Anna Caliò, (unknown), (unknown), Marco Schiavon, Maurizio Infante, Marco Damin, Claudio Micheletto, Lorenzo Belluomini, Liana Bonanno, (unknown), Valentina Guarneri, F. Calabrese, (unknown), Michele Stanislaw Milella, Pierfranco Conté	1
12	LBA85 REACTION: A phase II study of etoposide and cis/carboplatin with or without pembrolizumab in untreated extensive small cell lung cancer 2020 ·Annals of Oncology ·Benjamin Besse, Jessica Menis, Paolo Bironzo, R. Gervais, Laurent Greillier, I. Monnet, Lorenzo Livi, Robyn R. Young, C. Decroisette, Nicolas Cloarec, G. Robinet, Roland Schött, Raffaele Califano, Filippo de Marinis, Giuseppe Luigi Banna, Murielle Mauer, (unknown), Baktiar Hasan, Thierry Berghmans, Anne‐Marie C. Dingemans	18
13	Diagnosis and treatment of early and locally advanced non-small-cell lung cancer: The 2019 AIOM (Italian Association of Medical Oncology) clinical practice guidelines 2020 ·Critical Reviews in Oncology/Hematology ·Francesco Passiglia, Luca Bertolaccini, Marzia Del Re, Fabio Facchinetti, Roberto Ferrara, Tindara Franchina, Umberto Malapelle, Jessica Menis, Antonio Passaro, Sara Pilotto, Sara Ramella, Giulio Rossi, Rocco Trisolini, Silvia Novello	31
14	A randomized, phase 3 trial with anti-PD-1 monoclonal antibody pembrolizumab (MK-3475) versus placebo for patients with early stage NSCLC after resection and completion of standard adjuvant therapy (EORTC/ETOP 1416-PEARLS) 2017 ·Annals of Oncology ·Luis Paz‐Ares, Baktiar Hasan, Urania Dafni, Jessica Menis, (unknown), Kersti Oselin, István Albert, Martin Faehling, Paul Van Schil, Mary O’Brien	8
15	TPF plus cetuximab induction chemotherapy followed by biochemoradiation with weekly cetuximab plus weekly cisplatin or carboplatin: a randomized phase II EORTC trial 2017 ·Annals of Oncology ·Pol Specenier, Éva Remenár, Jan Buter, Dirk Schrijvers, Cristiana Bergamini, Lisa Licitra, Ahmad Awada, Paul M. Clément, Catherine Fortpied, Jessica Menis, Jan B. Vermorken	12
16	The APPLE Trial: Feasibility and Activity of AZD9291 (Osimertinib) Treatment on Positive PLasma T790M in EGFR-mutant NSCLC Patients. EORTC 1613 2017 ·Clinical Lung Cancer ·Jordi Remón, Jessica Menis, Baktiar Hasan, Aleksandra Peric, (unknown), Silvia Novello, Martin Reck, Thierry Berghmans, Bartosz Wasąg, Benjamin Besse, Rafał Dziadziuszko	77
17	Methodology of clinical trials in lung cancer. 2015 ·Padua Research Archive (University of Padova) ·Jessica Menis, Benjamin Besse, Denis Lacombe	1
18	Sunitinib (SU11248) in patients with chemo naive extensive small cell lung cancer or who have a ‘chemosensitive’ relapse: A single-arm phase II study (EORTC-08061) 2015 ·European Journal of Cancer ·(unknown), Egbert F. Smit, Baktiar Hasan, Jessica Menis, Sanjay Popat, Jan P. van Meerbeeck, Veerle Surmont, Paul Baas, Mary O’Brien	18
19	Spectalung: Screening Patients with Thoracic Tumors for Efficient Clinical Trial Access 2015 ·Annals of Oncology ·Benjamin Besse, Jessica Menis, Julien Adam, Rafał Dziadziuszko, (unknown), Ludovic Lacroix, Solange Peters, (unknown), Mary O’Brien, Rolf A. Stahel	2
20	A computational index derived from whole-genome copy number analysis is a novel tool for prognosis in early stage lung squamous cell carcinoma 2011 ·Genomics ·Ornella Belvedere, Stefano Berri, Rebecca Chalkley, Caroline Conway, Fabio Barbone, Federica Pisa, Kenneth MacLennan, Catherine Daly, (unknown), Joanne Morgan, Jessica Menis, (unknown), Kostas Papagiannopoulos, Pamela Rabbitts, Henry M. Wood	12

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact